Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis : Use of Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis
The purpose of this expanded access protocol is to provide, upon the treating clinician's request and Sponsor assessment, Voriconazole Inhalation Powder to patients with pulmonary aspergillosis, or patients with other voriconazole-sensitive pulmonary fungal infections, who have limited or no other treatment options or who have had unfavorable response to adequate standard of care antifungal therapy including to oral or intravenous voriconazole.Reporting of serious adverse events (SAE) and Adverse Events of Special Interest (AESI) are required under this expanded access protocol. Patient treatment and outcomes information are also intended to be gathered under this protocol to the extent feasible (e.g., disease progression/improvement after treatment)..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ClinicalTrials.gov - (2023) vom: 09. Juni Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: June 9, 2023, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2023, Last updated: June 14, 2023 |
|---|
| Study ID: |
NCT05897294 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG009307834 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG009307834 | ||
| 003 | DE-627 | ||
| 005 | 20230614011629.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230614s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG009307834 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT05897294 | ||
| 035 | |a (UBBS_Klinische_Studien)TFF-VE-001 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis |b Use of Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: June 9, 2023, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2023, Last updated: June 14, 2023 | ||
| 520 | |a The purpose of this expanded access protocol is to provide, upon the treating clinician's request and Sponsor assessment, Voriconazole Inhalation Powder to patients with pulmonary aspergillosis, or patients with other voriconazole-sensitive pulmonary fungal infections, who have limited or no other treatment options or who have had unfavorable response to adequate standard of care antifungal therapy including to oral or intravenous voriconazole.Reporting of serious adverse events (SAE) and Adverse Events of Special Interest (AESI) are required under this expanded access protocol. Patient treatment and outcomes information are also intended to be gathered under this protocol to the extent feasible (e.g., disease progression/improvement after treatment). | ||
| 650 | 2 | |a Infections | |
| 650 | 2 | |a Communicable Diseases | |
| 650 | 2 | |a Mycoses | |
| 650 | 2 | |a Aspergillosis | |
| 650 | 2 | |a Pulmonary Aspergillosis | |
| 650 | 2 | |a Invasive Pulmonary Aspergillosis | |
| 650 | 2 | |a Aspergillosis, Allergic Bronchopulmonary | |
| 650 | 2 | |a Lung Diseases, Fungal | |
| 650 | 4 | |a Study Type: Expanded Access | |
| 650 | 4 | |a Recruitment Status: Available | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 09. Juni |
| 773 | 1 | 8 | |g year:2023 |g day:09 |g month:06 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT05897294 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 09 |c 06 | ||